Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Romiplostim in Pediatric ITP
NCT02279173Phase 3Completed
- Sponsor
- Amgen
- Start
- Dec 2014
- Primary completion
- Aug 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 17
01
Overview
A Phase 3 trial of romiplostim in immune thrombocytopenia (ITP), sponsored by Amgen. Started Dec 2014; status: completed.
02
Drugs
romiplostim
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT02279173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02279173.